AC Immune SA is a Swiss biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative diseases through its proprietary SupraAgem technology platform. [1]
| Attribute | Details | [2]
|-----------|---------| [3]
| Ticker | NASDAQ: ACIU | [4]
| Headquarters | Lausanne, Switzerland |
| Founded | 2003 |
| CEO | Andrea Pfeifer |
| Employees | ~150 |
| Market Cap | ~$200 million (2024) |
| Drug | Mechanism | Phase | Indication |
|---|---|---|---|
| ACI-35.030 (Lipid) | Anti-pTau liposome vaccine | Phase 2 | AD |
| ACI-35.030 (MD) | Anti-pTau liposome vaccine | Phase 1b | AD |
| ACI-24 | Anti-amyloid beta vaccine | Phase 1 | AD |
| Drug | Mechanism | Phase | Indication |
|---|---|---|---|
| Crenezumab | Anti-amyloid beta mAb | Phase 2 | AD (preventive) |
| JBI-802 | - | Preclinical | AD/PD |
| Drug | Mechanism | Phase | Indication |
|---|---|---|---|
| JBI-802 | - | Preclinical | PD |
| Drug | Mechanism | Phase |
|---|---|---|
| ACI-7104 | Anti-alpha-synuclein mAb | Phase 1 (planned) |
AC Immune's proprietary vaccine platform enables generation of antibodies against disease-specific protein targets:
| Year | Revenue | Cash | Key Programs |
|---|---|---|---|
| 2023 | $25M | $120M | ACI-35, ACI-24 |
| 2022 | $20M | $140M | ACI-35, Crenezumab |
| 2021 | $18M | $150M | Crenezumab |
The ACI-35.030 liposomal tau vaccine is currently in the Phase 2 ABATE study (NCT05514158), evaluating safety and immunogenicity in patients with early Alzheimer's disease. This study builds on positive Phase 1b results showing robust antibody responses against phosphorylated tau[1:1][2:1].
AC Immune's development program incorporates tau PET imaging as a key biomarker for target engagement, using tracers like [18F]Flortaucipir to visualize tau pathology burden and track disease progression[3:1].
While the crenezumab program was discontinued, AC Immune maintains its relationship with Genentech/Roche for other potential programs. The company's expertise in tau and alpha-synuclein remains attractive for partnerships[4:1].
The partnership with Lundbeck focuses on alpha-synuclein-targeting therapies for Parkinson's disease and related disorders. This collaboration leverages AC Immune's SupraAgem platform for novel vaccine development[5].
The proprietary liposome delivery system offers several advantages:
AC Immune continues to expand its pipeline through:
As a mid-sized biotech focused specifically on neurodegenerative diseases, AC Immune occupies a unique position: